50
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

A 3D-QSAR CoMSIA study on 3-azolylmethylindoles as anti-leishmanial agents

, , , , &
Pages 299-309 | Received 14 Oct 2005, Accepted 27 Feb 2006, Published online: 01 Feb 2007

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Sergey Shityakov, István Puskás, Norbert Roewer, Carola Förster & Jens Broscheit. (2014) Three-dimensional quantitative structure–activity relationship and docking studies in a series of anthocyanin derivatives as cytochrome P450 3A4 inhibitors. Advances and Applications in Bioinformatics and Chemistry 7, pages 11-21.
Read now
Francis Giraud, Cedric Loge, Fabrice Pagniez, Damien Crepin, Sophie Barres, Carine Picot, Patrice Le Pape & Marc Le Borgne. (2009) Design, synthesis and evaluation of 3-(imidazol- 1-ylmethyl)indoles as antileishmanial agents. Part II. Journal of Enzyme Inhibition and Medicinal Chemistry 24:5, pages 1067-1075.
Read now
Patrice Le Pape. (2008) Development of new antileishmanial drugs – current knowledge and future prospects. Journal of Enzyme Inhibition and Medicinal Chemistry 23:5, pages 708-718.
Read now

Articles from other publishers (1)

Nafiseh Vahedi, Majid Mohammadhosseini & Mehdi Nekoei. (2020) QSAR Study of PARP Inhibitors by GA-MLR, GA-SVM and GA-ANN Approaches. Current Analytical Chemistry 16:8, pages 1088-1105.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.